心臓再同期療法によるベータアドレナジック・リザーブの強化のメカニズム
Khalid Chakir1, Samantapudi K Daya, Takeshi Aiba
1Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Circulation
|February 25, 2009
まとめ
心臓再同期療法 (CRT) は,筋細胞機能とアドレナージ信号伝達を強化することで心不全を改善します. この治療は,収縮シンクロニーを回復し,ベータ-アドレナジック反応を高め,心臓機能の改善につながります.
科学分野:
- 心臓病学 心臓病学
- 分子生物学は分子生物学である.
- 心不全に関する研究
背景:
- 心臓再同期療法 (CRT) は,心不全の重要な治療法であり,シストリック機能を改善し,死亡率を低下させます.
- CRTのメカニカル効果は知られているが,筋細胞機能とアドレネルギー調節に対する長期的な影響は不明である.
研究 の 目的:
- 心不全の犬のモデルにおける肌細胞機能とアドレネルギーシグナル伝達に対するCRTの長期的な影響を調査する.
主な方法:
- 左束の枝切除と心房短動を用い,非同期性心不全 (DHF) の犬モデルが作成されました.
- DHFの動物は3週間にわたってCRT (バイブントリキュラ・タキペーシング) を受け,DHFと対照群と比較した.
- 筋細胞機能,カルシウムトランジント,アドレネルギーシグナル伝達,および関連するタンパク質発現が分析されました.
主要な成果:
- CRTは収縮シンクロニティを回復し,DHFの動物でシストリック機能を改善しました.
- ミオサイト縮小とカルシウムトランジントは,休息状態とベータアドレネルジック刺激の間,CRTによって強化されました.
- CRTはベータ(1) 受容体の豊富さを増加させ,アデニラートサイクラースの活性を増やし,抑制的なGタンパク質シグナル伝達を抑制し,心筋カテキオラミンを減少させました.
結論:
- CRTは,静止状態と刺激状態で,筋細胞機能とカルシウム処理を大幅に改善します.
- ベータ""受容体とアデニル酸サイクラスの増調と,抑制されたG""i"結合シグナル伝達が,CRTの利点に寄与する.
- 神経刺激が低下したにもかかわらず,心臓機能の強化と交感準備は,心不全におけるCRTの純正効果の基礎となっている.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...